

JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis

MIHO SEKIMOTO¹, TADAHIRO TAKADA^{2,*}, YOSHIFUMI KAWARADA³, KOICHI HIRATA⁴, TOSHIHIKO MAYUMI⁵,
MASAHIRO YOSHIDA², MASAHICO HIROTA⁶, YASUTOSHI KIMURA⁴, KAZUNORI TAKEDA⁷, SHUJI ISAJI⁸,
MASARU KOIZUMI⁹, MAKOTO OTSUKI^{10,**}, and SEIKI MATSUNO^{11,***}

¹Department of Healthcare Economics and Quality Management, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan

²Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan

³Ueno Municipal Hospital, Mie, Japan

⁴First Department of Surgery, Sapporo Medical University School of Medicine, Hokkaido, Japan

⁵Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

⁶Department of Gastroenterological Surgery, Kumamoto University Graduate School of Medical Science, Kumamoto, Japan

⁷Department of Surgery, National Hospital Organization Sendai Medical Center, Sendai, Japan

⁸Department of Hepatobiliary Pancreatic Surgery and Breast Surgery, Mie University Graduate School of Medicine, Mie, Japan

⁹Ohara Medical Center Hospital, Fukushima, Japan

¹⁰Department of Gastroenterology and Metabolism, University of Occupational and Environmental Health, Japan, School of Medicine, Kitakyushu, Japan

¹¹Division of Gastroenterological Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan

Abstract

Acute pancreatitis is a common disease with an annual incidence of between 5 and 80 people per 100000 of the population. The two major etiological factors responsible for acute pancreatitis are alcohol and cholelithiasis (gallstones). The proportion of patients with pancreatitis caused by alcohol or gallstones varies markedly in different countries and regions. The incidence of acute alcoholic pancreatitis is considered to be associated with high alcohol consumption. Although the incidence of alcoholic pancreatitis is much higher in men than in women, there is no difference in sexes in the risk involved after adjusting for alcohol intake. Other risk factors include endoscopic retrograde cholangiopancreatography, surgery, therapeutic drugs, HIV infection, hyperlipidemia, and biliary tract anomalies. Idiopathic acute pancreatitis is defined as acute pancreatitis in which the etiological factor cannot be specified. However, several studies have suggested that this entity includes cases caused by other specific disorders such as microlithiasis. Acute pancreatitis is a potentially fatal disease with an overall mortality of 2.1%–7.8%. The outcome of acute pancreatitis is determined by two factors that reflect the severity of the illness: organ failure and pancreatic necrosis. About half of the deaths in patients with acute pancreatitis occur

within the first 1–2 weeks and are mainly attributable to multiple organ dysfunction syndrome (MODS). Depending on patient selection, necrotizing pancreatitis develops in approximately 10%–20% of patients and the mortality is high, ranging from 14% to 25% of these patients. Infected pancreatic necrosis develops in 30%–40% of patients with necrotizing pancreatitis and the incidence of MODS in such patients is high. The recurrence rate of acute pancreatitis is relatively high: almost half the patients with acute alcoholic pancreatitis experience a recurrence. When the gallstones are not treated, the risk of recurrence in gallstone pancreatitis ranges from 32% to 61%. After recovering from acute pancreatitis, about one-third to one-half of acute pancreatitis patients develop functional disorders, such as diabetes mellitus and fatty stool; the incidence of chronic pancreatitis after acute pancreatitis ranges from 3% to 13%. Nevertheless, many reports have shown that most patients who recover from acute pancreatitis regain good general health and return to their usual daily routine. Some authors have emphasized that endocrine function disorders are a common complication after severe acute pancreatitis has been treated by pancreatic resection.

Key words Pancreatitis · Epidemiology · Etiology · Survival rate · Treatment outcome

Offprint requests to: M. Sekimoto

* President, Japanese Society of Emergency Abdominal Medicine; President, Japanese Society of Hepato-Biliary-Pancreatic Surgery; President, Asian-Pacific Hepato-Pancreato-Biliary Association

** Chairman, Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour and Welfare

*** President, Japan Pancreas Society

Clinical questions

1. What is the incidence of acute pancreatitis? Is it different for different countries and areas?
2. What are the causes of acute pancreatitis?
3. What are the risk factors for developing acute pancreatitis?
4. What are the outcomes of acute pancreatitis?

Introduction

The Japanese Society for Emergency Abdominal Medicine, the Japanese Society of Hepato-Biliary-Pancreatic Surgery, and the Japan Pancreas Society have developed evidence-based clinical practice guidelines for acute pancreatitis that integrate all available evidence regarding the epidemiology and clinical management of acute pancreatitis published between 1960 and 2000.¹ In this article we have added a review of articles published since 2000, and we describe the epidemiology, etiology, natural history, and predictors of disease outcome in acute pancreatitis.

Clinical questions (CQ) 1. What is the incidence of acute pancreatitis? Is it different for different countries and areas?

Studies on the incidence of acute pancreatitis show large regional differences. Although the diagnostic criteria for acute pancreatitis vary for different countries, regions, and reports, those reports published since 2000 have revealed that the annual incidence rates of acute pancreatitis range from 5 to 80 per 100 000 (Table 1). Many studies of trends in the incidence of acute pancreatitis have suggested that the numbers have been increasing in recent years.^{8,9}

The first national survey in Japan was conducted in 1987 by the Research Group for Acute Pancreatitis and was organized by the Japanese Ministry of Health and Welfare. The survey targeted patients treated for acute pancreatitis between 1982 and 1986 at medical institutions selected by a stratified random sampling method. According to the survey, the number of acute pancreatitis patients in Japan was estimated to be 14 500/year [95% confidence interval (CI): 9500–19 500] and the es-

timated incidence of acute pancreatitis was 12.1/100 000. The second national survey estimated that the number of patients in 1998 was 19 500 (95% CI: 17 000–22 000) and the incidence was 15.4/100 000 (20.5/100 000 for men and 10.6/100 000 for women). The ratio of men to women was 1.9 to 1 and incidence peaked in the 7th decade of life in men and in the 8th decade in women (Fig. 1). Although the two surveys differed in terms of their subjects and methods of estimation, the incidence of acute pancreatitis is considered to be increasing (evidence level; Level 4).¹⁰ Epidemiological studies in Japan have encountered the following problems: the definition of acute pancreatitis in Japan includes acute exacerbations of chronic pancreatitis and the data are hospital-based and exclude autopsy cases. Nevertheless, the incidence of acute pancreatitis in Japan is generally considered to be below the average level found in other countries.

Table 2 summarizes the results of the national survey conducted in 1998. Severe acute pancreatitis accounted for 10.3% of all acute pancreatitis cases in the first survey and 25.3% in the second survey.^{11–13} However, it cannot be concluded from these statistics that the incidence of severe acute pancreatitis has increased, because different criteria were used to evaluate the severity of acute pancreatitis in the two surveys.

CQ2. What are the causes of acute pancreatitis?

The two major etiological factors responsible for acute pancreatitis are alcohol and cholelithiasis (gallstones).² The proportions of pancreatitis attributed to alcohol and gallstones in all cases of acute pancreatitis vary considerably for different countries and regions (Table 3).^{3–7,16,17} In Hungary, the incidence of alcoholic pancreatitis is two and a half times that of gallstone pancreatitis,¹⁴ and the high incidence of acute alcoholic

Table 1. Incidence of acute pancreatitis

Author (year)	Country/region	Subjects	Incidence (per 100 000/year)
Banks ² (2002)	England, the Netherlands	First attack/recurrence	5–10
	Scotland, Denmark	First attack/recurrence	25–35
	USA, Finland	First attack/recurrence	70–80
Tinto et al. ³ (2002)	UK	First attack/recurrence	14.5–20.7
Andersson et al. ⁴ (2004)	Sweden	First attack/recurrence	30
Lankisch et al. ⁵ (2002)	Germany	First attack/recurrence	19.7
Gislason et al. ⁶ (2004)	Norway	First attack/recurrence	30.6
		First attack	20
Birgisson et al. ⁷ (2002)	Iceland	First attack	32
Floyd et al. ⁸ (2002)	Denmark	Men	27.1
		Women	37.8
Japan National Survey (1987)	Japan	First attack/recurrence	12.1
Japan National Survey (1998)	Japan	First attack/recurrence (Total)	15.4
		First attack/recurrence (men)	20.5
		First attack/recurrence (women)	10.6




Fig. 1. Incidence of acute pancreatitis in Japan in 1998. Men, shaded bars; women, white bars

Table 2. Etiology and incidence of acute pancreatitis in Japan (national survey in 1999)

	All cases			Severe cases		
	Men (%)	Women (%)	Total (%)	Men (%)	Women (%)	Total (%)
Alcohol	466 (42)	42 (7.2)	508 (30)	138 (49)	14 (11)	152 (37)
Cholelithiasis	219 (20)	183 (31)	402 (24)	44 (16)	37 (30)	81 (20)
Abdominal injury	8 (0.7)	3 (0.5)	11 (0.7)	5 (1.8)	0 (0.0)	5 (1.2)
Surgery	25 (2.3)	18 (3.1)	43 (2.6)	4 (1.4)	3 (2.4)	7 (1.7)
ERCP	27 (2.5)	38 (6.5)	65 (3.9)	6 (2.1)	6 (4.8)	12 (2.9)
EST	12 (1.1)	16 (2.7)	28 (1.7)	5 (1.8)	8 (6.4)	13 (3.2)
Exacerbation of chronic pancreatitis	73 (6.6)	22 (3.7)	95 (5.6)	6 (2.1)	2 (1.6)	8 (2.0)
Pancreatic cancer	7 (0.6)	4 (0.7)	11 (0.7)	3 (1.1)	2 (1.6)	5 (1.2)
Pancreatobiliary maljunction	8 (0.7)	7 (1.2)	15 (0.9)	1 (0.4)	0 (0.0)	1 (0.2)
Pancreas divisum	5 (0.5)	3 (0.5)	8 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)
Autoimmune diseases	0 (0.0)	4 (0.7)	4 (0.2)	0 (0.0)	1 (0.8)	1 (0.2)
Hyperlipidemia	10 (0.9)	10 (1.7)	20 (1.2)	4 (1.4)	3 (2.4)	7 (1.7)
Drugs	10 (0.9)	11 (1.9)	21 (1.2)	4 (1.4)	4 (3.2)	8 (2.0)
Idiopathic	186 (16.9)	196 (33)	392 (23)	51 (18)	38 (30)	89 (22)
TAE/TAI for hepatoma	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Others	42 (3.8)	30 (5.1)	72 (4.3)	12 (4.2)	7 (5.6)	19 (4.7)
Subtotal	1098 (100)	587 (100)	1685 (100)	283 (100)	125 (100)	408 (100)
Blank	0	3	3	0	1	1
Total	1098 (100)	590	1688	283	126	409

ERCP, endoscopic retrograde cholangiopancreatography; EST, endoscopic sphincterotomy; TAE, transcatheter arterial embolization; TAI, transcatheter arterial infusion

pancreatitis is considered to be associated with high levels of alcohol consumption.¹⁸ In contrast, the incidence of gallstone pancreatitis is much higher than that of alcoholic pancreatitis in Greece, Italy, and Norway.^{6,14} In France, Germany, and Korea, the incidence of acute alcoholic pancreatitis is slightly higher than that for gallstone pancreatitis,^{14,16} whereas the opposite is true in Mexico and Sweden.^{4,17} According to a 1999 national survey done in Japan (Table 3), the incidence of acute alcoholic pancreatitis was fairly similar to that of gallstone pancreatitis (30% vs. 24%). However, the survey classified as alcoholic pancreatitis those cases in which the consumption of only a small amount of alco-

hol was identified before the onset of symptoms, so the incidence of alcoholic pancreatitis may have been overestimated. Thus, it remains unknown whether alcoholic pancreatitis or gallstone pancreatitis has a higher incidence in Japan.

Sex is strongly associated with the risk of acute pancreatitis: the incidence of alcoholic pancreatitis is higher in men, and the incidence of gallstone pancreatitis is higher in women.^{14,19} A study on acute pancreatitis in five European countries revealed that there were many more cases of alcoholic pancreatitis in men than women (90% vs. 10%).¹⁴ The 1999 survey done in Japan²⁰ also revealed that in women the incidence of gallstone pan-

Table 3. Etiology of acute pancreatitis by country

Author (year)	Country	Alcohol (%)	Cholelithiasis (%)	Others (%)
Gullo et al. ¹⁴ (2002)	Hungary	60.7	24.0	15.3
	France	38.5	24.6	36.9
	Germany	37.9	34.9	27.2
	Greece	6.0	71.4	22.6
	Italy	13.2	60.3	26.5
Cavallini et al. ¹⁵ (2004)	Italy	8.5	60	31.5
Andersson et al. ⁴ (2004)	Sweden	30	35	35
Gislason ⁶ (2004)	Norway	17	47	36
Kim ¹⁶ (2003)	Korea	32.5	26.6	40.9
Suazo-Barahona et al. ¹⁷ (1998)	Mexico	34	43	23
National survey (1998)	Japan	30	24	46

creatitis was higher than that of alcoholic pancreatitis (31% vs. 7.2%), whereas in men the incidence of acute alcoholic pancreatitis was twice that of gallstone acute pancreatitis (42% vs. 20%). A similar tendency was observed for severe cases (Table 3). However, a German study showed that there was no gender difference in the risk of acute pancreatitis after adjusting for alcohol intake.²¹

Tamakoshi et al. conducted a case-control study to investigate risk factors associated with the onset of acute pancreatitis.²² Consumption of more than 100 g of alcohol within 24 h before the onset was significantly associated with the risk of acute pancreatitis (odds ratio: 4.4, 95% CI: 1.3–15.5). Lower lipid intake was also associated with risk of acute pancreatitis; the risk was lower (odds ratio: 0.49) in the one-third of subjects with the highest lipid intake than in the one-third with the lowest lipid intake. Smoking and average sleep duration were not associated with increased risk of acute pancreatitis.

CQ3. What are the risk factors for developing acute pancreatitis?

Alcohol

Alcohol is one of the two major etiological factors responsible for acute pancreatitis and several studies have attempted to quantify the risk of acute alcoholic pancreatitis. According to a cohort study in Germany done between 1988 and 1995, the incidence of acute alcoholic pancreatitis among those with the highest alcohol intake (alcohol consumption ≥ 60 g/day) was 91.5/100 000 per year for men and 81.9/100 000 per year for women.²¹ However, even in the highest-risk group, the risk of acute alcoholic pancreatitis during a 25-year period was only 2%–3%. These findings suggest that factors other than alcohol also contribute to the occurrence of acute alcoholic pancreatitis.²³

Cholelithiasis

Cholelithiasis is another major etiological factor responsible for acute pancreatitis. According to a study done in the United States,²⁴ 89 (3.4%) of 2583 cholelithiasis patients developed pancreatitis during the follow-up period, and the relative risk (RR) for acute pancreatitis in the cholelithiasis patients was 14/35 for men and 12/25 for women. After adjusting for age and sex, the risk of acute pancreatitis among patients with gallstones was 6.3 to 14.8 per 1000 patient-years. However, the risk dramatically decreased after cholecystectomy to 1.9 per 1000 patient-years for men and 2.0 per 1000 patient-years for women. The RR was decreased to 1/8 in patients who underwent cholecystectomy, and recurrence developed in only 2 of the 58 patients after cholecystectomy (Level 2b).²⁴

Diehl et al. investigated clinical factors associated with the risk of acute biliary pancreatitis. Multivariate analyses showed that acute pancreatitis was associated with a stone diameter of less than 5 mm (odds ratio, 4.51; $P = 0.007$) and with mulberry-shaped gallstones (odds ratio, 2.25; $P = 0.04$) (Level 2c).²⁵

Endoscopic retrograde cholangiopancreatography/endoscopic sphincterotomy

Acute pancreatitis is one of the major complications of endoscopic retrograde cholangiopancreatography (ERCP). According to reports from the United States and Europe, the incidence of acute pancreatitis after diagnostic ERCP ranged from 0.4% to 1.5% (Level 2c).^{26–28} The incidence of complications resulting from endoscopic sphincterotomy (EST) and therapeutic ERCP was found to be higher than that resulting from diagnostic ERCP (Levels 2b);^{29,30} the incidence of acute pancreatitis after EST and therapeutic ERCP ranged from 1.6% to 5.4%,^{26,27,29–31} and the incidence of severe acute pancreatitis ranged from 0.4% to 0.7%.^{28,32}

Masci et al. conducted a meta-analysis of 15 prospective clinical studies on complications resulting from ERCP³³ and identified risk factors for post-ERCP acute pancreatitis. The relative risk of developing post-ERCP acute pancreatitis for suspected sphincter of Oddi dysfunction was 4.09 (95% CI: 3.37–4.96; $P < 0.001$); for women 2.23 (95% CI: 1.75–2.84, $P < 0.001$); for patients with previous pancreatitis 2.46 (95% CI: 1.93–3.12, $P < 0.001$); for precut sphincterotomy 2.71 (95% CI: 2.02–3.63, $P < 0.001$); and for pancreatic injection 2.2 (95% CI: 1.6–3.01, $P < 0.001$). The following factors have also been enumerated as additional risk factors for acute pancreatitis: absence of cholangiectasis,²⁶ bile duct diameter of less than 1 cm,^{31,34–36} older patients,^{26,37} difficulty in cannulation,^{31,38,39} and performance of pancreatography.^{26,35,40–42} Maldonado et al. reported that the combined use of ERCP and Oddi manometry markedly increased the risk of acute pancreatitis.⁴³ The incidence of pancreatitis in patients who underwent sphincter of Oddi manometry alone was significantly lower than that in patients who underwent both manometry and ERCP (9.3% vs. 26.1%, $P < 0.026$). The addition of EST to ERCP, however, had no impact on the risk of post-ERCP acute pancreatitis.⁴³ There were no consistent findings regarding the association between the use of low-osmolar (nonionic) contrast media and the risk of post-ERCP acute pancreatitis, and the issue is still being debated (Levels 1b-2b).^{29,30,44}

A few studies have investigated post-ERCP acute pancreatitis in Japan. In 1979, Nakajima et al. analyzed complications after therapeutic ERCP in 25 large medical institutions across Japan.⁴⁵ In that survey, EST was performed in 468 patients over a 5-year period; 9 (2%) of them developed pancreatitis, but none died. Another nationwide survey targeted 28 large medical institutions⁴⁶ and revealed that of the 14947 patients who underwent diagnostic or therapeutic ERCP between January 1995 and December 1998, 166 (1.1%) developed complications. Acute pancreatitis occurred in 89 (0.8%) of the patients who underwent diagnostic ERCP, and the incidence following therapeutic ERCP was 1.9%. The incidence of severe acute pancreatitis among the patients who underwent diagnostic ERCP and therapeutic ERCP was 0.07% and 0.1%, respectively. One patient who underwent therapeutic ERCP died, and the overall mortality was 0.007%. The mortality rate among patients who underwent therapeutic ERCP was 0.02%.

In the 1980s, there was a lawsuit brought in Japan after a patient treated by ERCP developed acute pancreatitis and died. In that case, the court decided that reparation had to be made for the loss. Since then, physicians involved in endoscopy and endoscopic treatment in Japan have striven to prevent acute pancreatitis, and the Japan Gastroenterological Endos-

copy Society has developed guidelines to prevent complications related to endoscopy and endoscopic treatment.⁴⁷

Surgery and medical procedures

The incidence of postoperative pancreatitis is high after surgery conducted near the pancreas, such as biliary tract procedures, gastric surgery, splenectomies, and splenorenal shunts (Level 4).^{48,49} Before the introduction of ERCP and laparoscopic cholecystectomy, the risk of postoperative acute pancreatitis in patients undergoing biliary surgery was reported to be as high as 10%, with a mortality of 30%–80%.⁵⁰ Z'graggen et al. compared the incidence of postoperative pancreatitis after laparoscopic cholecystectomy (LC) and found that the risk of pancreatitis increased after conversion to an open cholecystectomy; the incidence of pancreatitis after completed LC was 0.34%, whereas that after conversion was 0.96% ($P = 0.02$).⁵¹ It was possible to establish a biliary origin for the pancreatitis in 4 (12.5%) of the 32 patients with postoperative pancreatitis, and no evidence was found for a causative role of intraoperative cholangiography or trauma to the pancreas (Level 2c).⁵¹

There have been many reports of pancreatitis developing after cardiovascular surgery^{52–57} or transplantation (e.g., pancreas, liver, kidney, heart, or bone marrow).^{58–60} Ramsey and Podratz investigated the incidence of postoperative pancreatitis after gynecological and obstetric surgery and found that it was very low overall, occurring in only 1 of 17 000 surgical procedures (Level 2c).⁶¹

Other reports have shown the occurrence of acute pancreatitis following extracorporeal shock wave lithotripsy (ESWL) for gallbladder stones (2%),⁶² following transcatheter arterial embolization (TAE, 33%),⁶³ following percutaneous biliary drainage (PBD) (24% developed postprocedural hyperamylasemia and 10% developed postoperative acute pancreatitis),⁶⁴ following biliary stent insertion (11.5F stent, 3%; 10F stent, none),⁶⁵ following intraoperative irradiation (2/98, 2%),⁶⁶ and following continuous ambulatory peritoneal dialysis (CAPD) (0.46 per 100 treatment-years).⁶⁷ However, it remains unclear whether these procedures increase the risk of acute pancreatitis.⁶⁸

Drugs

Many studies have suggested associations between the use of drugs and the risk of acute pancreatitis, but direct associations have been demonstrated for only a small number of drugs (Table 4).^{69–80} The interval between drug administration and the onset of symptoms differs depending on the drug. Certain drugs, such as ace-

Table 4. Drugs that have been reported to cause acute pancreatitis

L-Asparaginase (anticancer drug)
Azathioprine (immunosuppressant)
Didanosine (anti-HIV drug)
Estrogen
Furosemide (diuretic)
Pentamidine (for pneumocystis carinii infection)
6-Mercaptopurine (anticancer drug)
Salicylates (antipyretic drug)
Stibogluconate sodium (antiprotozoal drug)
Sulfonamide (antimicrobial drug)
Sulindac (antipyretic drug)
Vincristine (anticancer drug)
Vinblastine (anticancer drug)

taminophen, can cause pancreatitis after a single dose. Others, such as azathioprine, 6-mercaptopurine, metronidazole, aminosaliculates, and sulfonamides, characteristically can cause pancreatitis within a month after exposure, while still others, such as pentamidine, valproic acid, and didanosine, appear to cause injury weeks or months after exposure, possibly through the accumulation of a toxic metabolite (Level 4).⁸⁰

The drugs reported to be associated with the highest incidence of acute pancreatitis are azathioprine, mercaptopurine, and didanosine. An early study on the risk of acute pancreatitis associated with 6-mercaptopurine reported that 13 (3.3%) of 400 patients with inflammatory bowel disease developed acute pancreatitis.⁸¹ However, a case-control study of 490 000 residents of Denmark⁸² showed that the risk of acute pancreatitis in patients under treatment with azathioprine was only 1/659. In that study, the odds ratio for the risk of acute pancreatitis within 90 days after azathioprine administration was 7.5 (95% CI: 2.6–21.6), and after adjusting for cholelithiasis, alcohol, inflammatory intestinal diseases, and steroids, the odds ratio was 8.4 (95% CI: 2.6–21.6). Although many HIV patients treated with didanosine develop acute pancreatitis,^{83–85} the independent risk associated with use of the drug is unknown (See HIV infection, below).

According to a case-control study done in Sweden over a 4-year period, 462 of the 1.4 million registered residents aged between 20 and 85 who did not have a clear etiological factor for their acute pancreatitis were hospitalized on their first attack of acute pancreatitis. A multivariate analysis revealed that H2 blockers, proton pump inhibitors, NSAIDs, and antacids were significantly associated with the risk of acute pancreatitis, but the odd ratios were generally low (1.9–2.4).⁸⁶

Hyperlipidemia

High blood triglyceride levels of more than 1000–2000 mg/dl are said to increase the risk of acute pancre-

atitis.⁸⁷ Type V hyperlipidemia, as well as types I and IV, are prominent causes of acute pancreatitis as a result of marked hyperlipidemia (Level 4).⁸⁸ Secondary hyperlipidemia is caused by alcohol intake, pregnancy, estrogen therapy, and diabetes mellitus, all of which are risk factors for acute pancreatitis. Genetic polymorphism of lipoprotein lipase and the apolipoprotein C-II defect, which cause hyperlipidemia, are also suggested to cause acute pancreatitis (Level 4).^{89,90} Some recent studies have suggested an association between the risk of acute pancreatitis and marked hypertriglyceridemia related to the administration of protease inhibitors among patients with HIV infection.^{91,92} However, other reports argue that there is no association between the two.^{87,93}

The risk of acute pancreatitis associated with hyperlipidemia has yet to be determined. A large-scale cohort study showed that hyperlipidemia accounts for 12%–38% of all cases of acute pancreatitis,⁹⁴ whereas another study suggested that it accounts for only 1.3%–3.8%.⁹⁵

HIV infection

Acute pancreatitis is one of the main complications of acquired immunodeficiency syndrome (4%–22%), and the risk increases with the progression of HIV infection.⁷¹ The risk of acute pancreatitis in HIV-infected populations is 35 to 800 times higher than in populations without infection.^{83–85} Although HIV-infected patients may develop pancreatitis for many reasons, drugs are a common cause of acute pancreatitis. Before the introduction of antiretroviral therapy, the major mechanisms responsible for the development of acute pancreatitis among HIV-infected patients were: (1) pancreatic toxicity resulting from drugs used to treat HIV infection and (2) immunosuppression by the HIV infection itself.^{87,96,97} Since 1996, when protease inhibitors were released on the market and came to be widely used in the treatment of HIV infection, HIV-infected patients have had a higher incidence of medication-associated hypertriglyceridemia, which is often severe and difficult to treat, and several reports have suggested that hypertriglyceridemia may be involved in the onset of acute pancreatitis.^{91,92}

Bush and Kosmiski investigated whether the release of protease inhibitors onto the market changed the incidence of acute hyperlipidemic pancreatitis in HIV-infected patients.⁸⁷ Despite the well-established association between protease inhibitors and hyperlipidemia, there was no significant increase in the prevalence of hyperlipidemic patients in the HIV-infected population: the incidence of acute pancreatitis attributed to hypertriglyceridemia (serum neutral fat level ≥ 1000 mg/dl) was 3.3% before the sale of protease inhibitors (1990–1995) and 3.7% after they came on the

market (1996–2001) ($P = 0.6$). On the other hand, medication-induced pancreatitis was the most common kind in HIV-infected patients: the incidence of medication-induced acute pancreatitis was 46.6% before the release of protease inhibitors and 50.0% after the release ($P = 0.6$).

Idiopathic

After gallstones and alcohol, the third most common etiology of acute pancreatitis, regardless of country, region, or case series, is idiopathic. Acute idiopathic pancreatitis is defined as acute pancreatitis with a nonspecified etiological factor, but it includes those cases caused by other specific disorders. Two prospective studies of apparently idiopathic pancreatitis have found that two-thirds to three-quarters of the cases had microlithiasis documented by biliary-drainage studies, follow-up sonograms, and ERCP (Level 2b).^{98,99} In the treatment of acute pancreatitis, the diagnosis of acute idiopathic pancreatitis should be minimized by identifying the etiological factors based on clinical symptoms and findings as well as appropriate tests.

Other factors associated with acute pancreatitis

Other factors associated with acute pancreatitis are inherited conditions,^{94,96} pregnancy,^{100–102} trauma,^{103,104} viral infections (mumps, Coxsackie B, hepatitis B, cytomegalovirus, herpes simplex II, and varicella-zoster), bacterial infections (*Salmonella typhi*, *Leptospira*, and *Legionella*), fungal infection (*Aspergillus*), parasites (*Toxoplasma*, *Cryptosporidium*, *Ascaris lumbricoides*, and *Mycoplasma*¹⁰⁵), collagen diseases (including systemic lupus erythematosus,^{106–108} rheumatoid arthritis,¹⁰⁹ Sjogren's syndrome,¹¹⁰ and systemic sclerosis^{111–112}), hyperparathyroidism,^{113–116} and end-stage renal failure.^{117,118}

Many studies have suggested the involvement of local predisposing anatomic factors in the etiology of acute pancreatitis. The presence and diameter of a common channel, pancreatic duct reflux, the angle formed between the common bile duct and the pancreatic duct, abnormalities of the Vater's ampulla (edema, hemorrhage, and impacted calculi), patent Santorini's duct, and the position of confluence with the cystic duct have all been suggested to be associated with the development of acute pancreatitis (Levels 2b–3b).^{119–122} Pancreas divisum, a congenital variant of pancreatic ductal anatomy that affects 5%–7% of the general population, has also been suggested to be associated with acute pancreatitis. Some reports have shown a significantly higher incidence of pancreas divisum among patients with acute pancreatitis, including recurrent pancreatitis (Levels 3b–4).^{123,124} However, another study reported no difference in any of these parameters between acute

pancreatitis patients and healthy subjects (Level 2b).¹²⁵ A randomized controlled clinical trial showed that stenting of the accessory papilla interrupted the cycle of recurrent attacks of pancreatitis in patients with pancreas divisum (Level 1b).¹²⁶ Associations between acute pancreatitis and choledochocoele (choledochal cyst),^{127,128} peripapillary diverticulum,¹²⁹ ectopic pancreas,¹³⁰ pancreatitis caused by duodenal duplication,¹³¹ pancreatitis accompanying Caroli's disease,¹³² and pancreatitis caused by tumors of the pancreas (cancer of the pancreas,^{133–135} metastatic pancreatic tumors,¹³⁶ and carcinoid tumors¹³⁷) have also been reported (Level 4). However, it remains unclear whether the incidence of acute pancreatitis is higher in these patients than in healthy subjects.

Acute pancreatitis in childhood is unusual, and the etiology in children differs from the etiology in adults. Steinberg and Tenner reviewed 5 studies involving a total of 223 children with acute pancreatitis⁸⁰ and reported that trauma is the leading cause of acute pancreatitis in children, accounting for 21% of the cases, followed by idiopathic causes (20%), biliary tract disease (17%), drugs (15%), infections (10%), congenital anomalies (6%), and miscellaneous causes (11%).

CQ4. What are the outcomes of acute pancreatitis?

Recurrence of acute pancreatitis

The rate of recurrence of acute pancreatitis is relatively high, although it depends on etiological factors and interventions in response to those factors. A study of 1376 inpatients with acute pancreatitis (2211 episodes) during the 22-year period from 1975 to 1996 at a university hospital in Sweden revealed that 21% had had a recurrence and that two-thirds of them had experienced the recurrence within 3 months of the first attack.⁴ According to a prospective cohort study on the recurrence of acute alcoholic pancreatitis,¹³⁸ 46% had a recurrence of the disease, and 80% of the recurrent episodes developed within 4 years of the first attack. The recurrence rate did not change over time (Level 1b). Several studies have reported that the risk of recurrence of gallstone pancreatitis ranges from 32% to 61% when the gallstones are not treated at the initial hospitalization.^{139–141} On the other hand, another report has shown that idiopathic pancreatitis recurred on average in 1 of 31 patients during the subsequent 3 years (Level 1b).¹⁴² Lee et al. prospectively studied 23 patients who were diagnosed with idiopathic acute pancreatitis but had microscopic evidence of biliary sludge, and they found that the 12 patients who were treated by cholecystectomy or papillotomy had fewer recurrences than the 11 untreated patients ($P = 0.01$) (Level 1b).⁹⁹

In Japan, a study group on acute pancreatitis conducted a follow-up survey of 204 patients with severe acute pancreatitis who survived to discharge (excluding 27 late deaths) between 1982 and 1987.¹⁴³ The results of the survey showed that the overall recurrence rate for acute pancreatitis over the long term was 37%. Forty-eight percent of the patients received treatment for recurrent acute pancreatitis, as well as for complications such as diabetes mellitus and pancreatic pseudocyst, and 56% of those cases required hospitalization. The recurrence rates differed between various etiologies. The recurrence rate in patients with alcoholic pancreatitis was 51%, which was significantly higher than that among those with other etiological factors (Level 2b).¹⁴³ Whereas 67% of patients with alcoholic pancreatitis received medical treatment, only 29% of those with gallstone pancreatitis required medical treatment. However, the following must be taken into consideration when interpreting this survey: (1) the subjects were restricted to severe cases, (2) some cases with a favorable course may not have been included in the survey, and (3) some cases of chronic pancreatitis may have been classified as recurrent cases.

Development of chronic pancreatitis

The incidence of chronic pancreatitis after acute pancreatitis ranges from 3% to 13% (Levels 2b–4).^{144,145} Angelini et al. investigated the frequency of residual ductal lesions in 118 patients who had recovered from acute pancreatitis. Occlusive pancreatitis was identified

by ERCP in 7 patients (8.4%) who had recovered from necrotizing pancreatitis, and calcified pancreatitis was observed in 3 such patients (3.6%). Both percentages were higher than they were for those patients who had recovered from edematous pancreatitis (Level 1b).¹⁴⁶ A nationwide survey on the long-term outcome in severe pancreatitis patients in Japan revealed that pancreatic calculi were subsequently identified in 17% of such patients (33.5% of the alcoholic pancreatitis patients and 6.5% of the gallstone pancreatitis patients) and glucosuria was identified in 27% (40% of the alcoholic pancreatitis patients and 14% of the gallstone pancreatitis patients) (Level 2b).¹⁴⁶ These data suggest that the severity of, and the etiological factors for, pancreatitis are closely associated with the development of chronic pancreatitis.

Mortality

Many cases of acute pancreatitis are first diagnosed at autopsy. Reports in the 1980s (Levels 2b–4)^{147,148} showed that the diagnosis was made at necropsy in about 30%–40% of fatal cases of acute pancreatitis. Recent reports have also shown that the diagnosis of acute pancreatitis was made at necropsy in 12%–33% of fatal cases.^{149,150}

The case fatality of acute pancreatitis depends on the diagnostic criteria, as well as on whether autopsied cases are included.¹⁵¹ Studies published after 1990 have shown that the case fatality of acute pancreatitis in the United States and Europe ranges from 2.1% to 7.8% (Levels 1b–2b) (Table 5).^{147,149,151} Many studies have suggested that age is the primary risk factor for death

Table 5. Mortality from acute pancreatitis

Author	Study period	Setting/ country	All cases	Deaths	Mortality (%)
Andersson et al. ⁴	1975–1985	University hospital, Sweden			4.7
	1986–1996	University hospital, Sweden			3.7
Mann et al. ¹⁴⁹	1988–1992	Northwest Thames region, UK	631	57	9.0
Talamini et al. ¹⁵²	1976–1992	University hospital, Italy	192 ^a	17	8.8
Lowham et al. ¹⁵³	1996–1997	Infirmery, England	105	6	5.7
Mutinga et al. ¹⁵⁴	1982–1995	Large tertiary care hospital, USA	805	17	2.1
Blum et al. ¹⁵⁵	1988–1999	Luneburg County, Germany	351	17	4.6
Floyd et al. ⁸	1981–1985	Denmark	480	44	9.2
	1986–1990	Denmark	475	40	8.4
	1991–1995	Denmark	609	40	6.6
	1996–2000	Denmark	786	53	6.7
Lankisch et al. ⁵	1988–1995	Germany	228	16	7.0
Gullo et al. ¹⁴	1990–1994	Hungary, Germany, France, Italy, Greece	1068	83	7.8
Kim ¹⁶	1980–1989	Korea			3.0
	1990–1994	Korea			4.4
	1995–1999	Korea			2.1
Kandasami et al. ¹⁵⁶	1994–1999	Malaysia	133		7.5
National survey ¹⁵⁷	1995–1998	Japan	1240	92	7.4

^aFirst attack cases only

(Level 1b).^{150,151} A Japanese survey done from 1991 to 1995 showed that the mortality of severe acute pancreatitis is greater than 20% in patients over 50 years of age (Level 1b).¹⁵⁸ According to a 1988 nationwide survey done in Japan,¹² acute pancreatitis mortality was 2% in moderate cases and 30% in severe cases (Level 4). According to a 1999 nationwide surveillance,²⁰ overall mortality was 7.4% and 22% in the severe cases in Japan (Level 4).

There is a debate as to whether the mortality of acute pancreatitis has been decreasing in recent years. A few studies have suggested that the in-hospital mortality is declining. Andersson et al. reported that the hospital mortality of acute pancreatitis in a university hospital in Sweden decreased slightly, from 4.7% (1975–1985) to 3.7% (1986–96), and that the average age of the patients who died markedly increased, from 59.2 to 73.6 years of age.⁴ Tinto et al. have also shown a significant decline in the hospital mortality rate for acute pancreatitis between the periods 1989–1990 and 1999–2000, during which the age standardized hospital admission rate for acute pancreatitis increased by 43%.³ We must be careful in interpreting such data, because the level of patient risk and the patient background may be different between the study periods.

Mortality among patients with recurrent attacks is generally lower than among those experiencing their first attack. A study of 737 hospitalized patients with acute pancreatitis in Bristol, England, revealed that the overall mortality between 1968 and 1979 was 20%, but it was 12% in the patients with recurrent pancreatitis (Level 4).¹⁵⁹ Another hospital-based study showed that the mortality of patients with relapsing attacks (2.5%) was significantly lower than the overall mortality (4.2%) among acute pancreatitis patients.⁴ A European study of acute pancreatitis that selected 1068 patients in

5 countries (Hungary, Germany, Greece, Italy, and France) also showed significantly lower mortality in recurrent pancreatitis than was the overall mortality from acute pancreatitis (5.9% vs. 7.8%).^{14,152}

Factors associated with prognosis

The prognosis of acute pancreatitis is determined by two factors that reflect the severity of the disease: organ failure and pancreatic necrosis. Pancreatic necrosis can be evaluated by dynamic contrast-enhanced computed tomography (CT) scanning.^{160,161} According to the definitions of the 1992 Atlanta Symposium, the criteria for organ failure include the following parameters: (1) shock — systolic blood pressure <90 mmHg, (2) respiratory failure — PaO₂ <60 mmHg, (3) renal failure — serum creatinine >2 mg/dl after hydration, and (4) gastrointestinal bleeding — blood loss >500 ml/24 h. The Research Group sponsored by JMHW has established independent criteria for the assessment of the severity,¹⁶² and the parameters include dyspnea; shock; central nervous system disorders; bleeding tendency; negative base excess; and signs of organ failure, including elevation of the blood urea nitrogen level and the creatinine level.

Timing of death in acute pancreatitis

Many acute pancreatitis patients die within the first few weeks of the onset of the illness. According to reports published since 2000, about half of the deaths occur within the first 1–2 weeks, and they are mainly the result of multiple organ dysfunction syndrome (MODS)^{154,155} (Table 6). In general, late mortality in patients with severe acute pancreatitis results mainly from complications caused by infection, particularly by infectious pan-

Table 6. Comparison of mortality and time of death in acute pancreatitis [National Survey Data (Japan) added to data from the review by Blum et al.]

Author	Number of cases	Overall mortality		Proportion of early deaths (%)		Proportion of late deaths (%)	
		<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Mann et al. ¹⁴⁹	631	57	9	18	32 ^a	39	68
Talamini et al. ¹⁵²	192	17	9	14	82 ^b	3	18
Lowham et al. ¹⁵³	105	6	6	6	100 ^a	—	—
McKay et al. ¹⁵¹	NA	NA	8	NA	54 ^a	— ^c	46
Mutinga et al. ¹⁵⁴	805	8	2	8	47 ^b	9	53
Blum et al. ¹⁵⁵	368	17	5	7	41 ^a	10	59
National Survey	1131	67 ^d	6	19	28 ^a	48	72
(Japan) ¹⁵⁷	1131	67 ^d	6	27	40 ^b	40	60

^aEarly mortality was defined as death within 1 week

^bEarly mortality was defined as death within 2 weeks

^cNo single piece of data given

^dIncludes only the 67 cases in which acute pancreatitis was presumed to be the cause of death among a total of 94 fatal cases

Table 7. Mortality from acute necrotizing pancreatitis

Author (year)	Acute pancreatitis, all causes		Severe acute pancreatitis		Necrotizing acute pancreatitis	
	<i>n</i>	Mortality (%)	<i>n</i>	Mortality (%)	<i>n</i>	Mortality (%)
Karimani et al. ¹⁷³ (1992)			26 ^a	38		
Bradley and Allen ¹⁷⁴ (1991)	194				38	15
Rattner et al. ¹⁷⁵ (1992)					73	25
Allardyce ¹⁷² (1987)	348	5.2	43	33	17	80
Perez et al. ¹⁷⁰ (2002)	1110				99	14
Gullo et al. ¹⁴ (2002)	1068	7.8			479	16
Lankisch et al. ¹⁷⁶ (2002)	326	7.1			64	
Japan's national survey ¹⁷⁷ (2000)	1240	7.4	409	22	117	23

^a Patients with at least one systemic complication

creatic necrosis (Levels 2c–4).^{163–165} Gloor et al. have argued that early mortality associated with acute pancreatitis has decreased as a result of modern intensive care treatment.¹⁶⁶ In their case series, the overall mortality rate was 4% and the mortality rate in patients with necrotizing pancreatitis was 9%. On the other hand, some argue that many patients with acute pancreatitis still die within the first 1–2 weeks after admission.¹⁶⁷ In a large study of acute pancreatitis in the United Kingdom, 35 deaths occurred among 283 patients with severe acute pancreatitis, and 13 of those occurred within the first week of illness.¹⁶⁸ Japanese surveys define early mortality as death within 2 weeks of admission, and the early mortality rate was 52% in the period 1982–1986; it then markedly decreased to 29% in 1996.¹⁶⁹ According to a 1988 survey, shock followed by severe dehydration was the leading cause of early death, and the cause of those deaths that occurred after 2 weeks included renal failure, respiratory failure, gastrointestinal hemorrhage, sepsis, and shock (Level 2c).^{12,13} According to a 1999 survey,¹⁵⁷ acute pancreatitis was the direct cause of death in 67 (73%) of 92 cases. Twenty-seven deaths (40%) occurred within 2 weeks of onset, and MODS accounted for 85.2% of these. Another 40 deaths occurred 2 weeks or more after onset, and MODS, including sepsis (67.5%) and disseminated intravascular coagulation syndrome (62.5%), accounted for as many as 87.5% of those deaths.

Necrotizing pancreatitis

Depending on patient selection, necrotizing pancreatitis develops in approximately 10%–20% of acute pancreatitis patients, and mortality is high; however, mortality is only 1%–3% among those without necrotizing pancreatitis.^{14,170,171} A report from the 1980s indicated a mortality of 80% among patients with necrotizing pancreatitis,¹⁷² whereas figures from the 1990s have ranged

from 14% to 25% (Table 7). According to a Japanese survey done in 1999,²⁰ 409 (33%) of the patients developed a severe disease. Contrast-enhanced CT scanning was performed in 75% of these patients, and pancreatic necrosis was observed in 42% of them. Based on these findings, the incidence of pancreatic necrosis in Japan is estimated to be 10%–15% (Level 3b). In this survey, the mortality of severe acute pancreatitis with pancreatic necrosis was 23%, whereas the mortality in severe acute pancreatitis without pancreatic necrosis was 11%.

It has been suggested that the outcome of necrotizing pancreatitis is associated with the extent of necrosis and infectious complications (Level 4).^{169,178} Perez et al. classified 99 patients with necrotizing pancreatitis into two groups according to the extent of necrosis (<50% or ≥50%); they compared outcomes between the two groups but found no significant difference in the Acute Physiology and Chronic Health Evaluation (APACHE) II scores, the incidence of infected necrosis, MODS, or organ failure. MODS and organ failure were strongly associated with death. When organ failure accompanied necrotizing pancreatitis, mortality increased to 47%; mortality among the patients with MODS was 49%.¹⁷⁰

According to reports from the United States and Europe, infected pancreatic necrosis develops in 30%–40% of patients with necrotizing pancreatitis.¹⁷⁰ A 1999 survey done in Japan revealed that infected pancreatic necrosis occurred in 152 (41%) of the 367 patients (42 patients with unconfirmed infection were excluded from 409 severe acute pancreatitis patients), and mortality was 34% in infected pancreatic necrosis, as opposed to only 7% in pancreatic necrosis without infection. According to the report by Perez et al., the mortality in infected necrosis was 19% (7/37), as opposed to only 11% (7/62) in sterile necrosis. Although the difference in mortality between these groups was not statistically significant, the incidence of multiple organ failure, which strongly affects the outcome, was much higher in

the infected necrosis patients than in the sterile necrosis patients (41% vs. 23%, $P = 0.07$). It cannot be denied that necrotizing pancreatitis is strongly linked to the outcome.

Long-term outcome

About one-third to one-half of acute pancreatitis patients develop functional disorders of both the endocrine system and the exocrine system (diabetes mellitus and fatty stool). However, many reports have shown that most patients are in good general health at the time of discharge and return to their usual daily routine (Level 4).^{156,179,180} Although the age-standardized mortality rate of patients who recovered from acute pancreatitis is higher than those without the disease, the mortality was no different among patients over 65 years of age (Level 4).¹⁴³ Symptoms tend to decrease with time among patients with fatty stool, whereas the symptoms of diabetes mellitus deteriorate (Level 1b).¹⁸¹ On the other hand, some authors have emphasized that endocrine function disorders after severe acute pancreatitis are associated with pancreatic resection (Level 2b),¹⁸² since insulin secretion is significantly decreased after pancreatic resection compared with conservative treatments such as peritoneal lavage.

In 1999, a survey was done by the Japanese Ministry of Health, Labour and Welfare that targeted 2098 patients who had experienced severe acute pancreatitis in 1987.¹⁸³ Information was gathered on 714 (34%) of those patients. Some 15% had died, 22% had experienced a recurrence, 24% had progressed to chronic pancreatitis, and 13% had developed diabetes mellitus. Some 80% of the respondents had been able to return to their usual daily routine, i.e., the same routine that they had enjoyed before the onset of the disease. The most frequent cause of death was a malignant tumor (36%). Forty-six percent of the patients who had a recurrence experienced it within 1 year of the initial attack.¹⁸³

References

1. Mayumi T, Ura H, Arata S, Kitamura N, Kiriya I, Shibuya K, et al. Working Group for the Practical Guidelines for Acute Pancreatitis. Japanese Society of Emergency Abdominal Medicine. Evidence-based clinical practice guidelines for acute pancreatitis: proposals. *J Hepatobiliary Pancreat Surg* 2002;9(4): 413–22.
2. Banks PA. Epidemiology, natural history, and predictors of disease outcome in acute and chronic pancreatitis. *Gastrointest Endosc* 2002;56(6 Suppl):S226–30.
3. Tinto A, Lloyd DA, Kang JY, Majeed A, Ellis C, Williamson RC, Maxwell JD. Acute and chronic pancreatitis — diseases on the rise: a study of hospital admissions in England 1989/90–1999/2000. *Aliment Pharmacol Ther* 2002;16(12):2097–105.
4. Andersson R, Andersson B, Haraldsen P, Drewsen G, Eckerwall G. Incidence, management, and recurrence rate of acute pancreatitis. *Scand J Gastroenterol* 2004;39(9):891–4.
5. Lankisch PG, Assmus C, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic diseases in Luneburg County: a study in a defined German population. *Pancreatol* 2002;2(5): 469–77.
6. Gislason H, Horn A, Hoem D, Andren-Sandberg A, Imsland AK, Soreide O, Viste A. Acute pancreatitis in Bergen, Norway: a study on incidence, etiology, and severity. *Scand J Surg* 2004;93(1):29–33.
7. Birgisson H, Moller PH, Birgisson S, Thoroddsen A, Asgeirsson KS, Sigurjonsson SV, Magnusson J. Acute pancreatitis: prospective study of its incidence, aetiology, severity, and mortality in Iceland. *Eur J Surg* 2002;168(5):278–82.
8. Floyd A, Pedersen L, Nielsen GL, Thorladius-Ussing O, Sorensen HT. Secular trends in incidence and 30-day case fatality of acute pancreatitis in North Jutland County, Denmark: a register-based study from 1981–2000. *Scand J Gastroenterol* 2002;37(12):1461–5.
9. Lindkvist B, Appelros S, Manjer J, Borgstrom A. Trends in incidence of acute pancreatitis in a Swedish population: is there really an increase? *J Clin Gastroenterol Hepatol* 2004;2(9):831–7.
10. Otsuki M. Survey of deterioration in acute pancreatitis: 2002 Report. Tokyo: The Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour and Welfare; 2003. p. 32–40.
11. The Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour and Welfare. Matsuno M, editor. Guidelines for management of severe acute pancreatitis: pathophysiology of severe acute pancreatitis. Tokyo: Igaku Tosho; 1997. p. 2–3.
12. Yamamoto M. Clinical statistics of severe acute pancreatitis in Japan. In: Saito Y, editor. Guideline for management of severe acute pancreatitis. Tokyo: Kokusai Tosho; 1991. p. 11–26.
13. Yamamoto M, Saitoh Y. Severe acute pancreatitis in Japan. *J Hepatobiliary Pancreat Surg* 1996;3:203–9.
14. Gullo L, Migliori M, Olah A, Farkas G, Levy P, Arvanitakis C, et al. Acute pancreatitis in five European countries: etiology and mortality. *Pancreas* 2002;24(3):223–7.
15. Cavallini G, Frulloni L, Bassi C, Gabbriellini A, Castoldi L, Costamagna G, et al. ProInf-AISP Study Group prospective multicentre survey on acute pancreatitis in Italy (ProInf-AISP): results on 1005 patients. *Dig Liver Dis* 2004;36(3):205–11.
16. Kim CD. Current status of acute pancreatitis in Korea. (in Korean) *Korean J Gastroenterol* 2003;42(1):1–11.
17. Suazo-Barahona J, Carmona-Sanchez R, Robles-Diaz G, Milke-Garcia P, Vargas-Vorackova F, Uscanga-Dominguez L, Pelaez-Luna M. Obesity: a risk factor for severe acute biliary and alcoholic pancreatitis. *Am J Gastroenterol* 1998;93(8):1324–8.
18. Jaakkola M, Nordback I. Pancreatitis in Finland between 1970 and 1989. *Gut* 1993;34:1255–60.
19. Lankisch PG, Assmus C, Lehnick D, Maisonneuve P, Lowenfels AB. Acute pancreatitis: does gender matter? *Dig Dis Sci* 2001;46(11):2470–4.
20. Hayashi O, Tamakoshi A, Ohno Y, Kawamura T, Ogawa M, Hirota M. Survey of deterioration in acute pancreatitis; 1999 Report. Tokyo: The Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour and Welfare; 2000. p. 72–8.
21. Lankisch PG, Lowenfels AB, Maisonneuve P. What is the risk of alcoholic pancreatitis in heavy drinkers? *Pancreas* 2002;25(4): 411–12.
22. Tamakoshi A, Hayashi O, Ogawa M, Hirota M, Atomi H, Otsuki M, et al. Case control study of risk factors of acute pancreatitis; 2001 Report. Tokyo: The Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour and Welfare; 2002. p. 47–59.

23. Dufour MC, Adamson MD. The epidemiology of alcohol-induced pancreatitis. *Pancreas* 2003;27(4):286–90.
24. Moreau JA, Zinsmeister AR, Melton L III, DiMagna EP. Gallstone pancreatitis and the effect of cholecystectomy: a population-based cohort study. *Mayo Clin Proc* 1988;63:466–73.
25. Diehl AK, Holleman DJ, Chapman JB, Schwesinger WH, Kurtin WE. Gallstone size and risk of pancreatitis. *Arch Intern Med* 1997;157:1674–8.
26. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: Prospective multicenter study. *Gastrointest Endosc* 1998;48:1–10.
27. Lenriot JP, Le Neel JC. Catheterisme retrograde et sphincterotomie endoscopique Evaluation prospective en milieu chirurgical. *Gastroenterol Clin Biol* 1993;17:244–50.
28. Reiertsen O, Skjoto J, Jacobsen CD, Rosseland AR. Complications of fiberoptic gastrointestinal endoscopy — five years' experience in a central hospital. *Endoscopy* 1987;19:1–6.
29. Sherman S, Hawes RH, Rathgeber SW, Uzer MF, Smith MT, Khusro QE, et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent. *Gastrointest Endosc* 1994;40:422–7.
30. Johnson GK, Geenen JE, Bedford RA, Johanson J, Cass O, Sherman S, et al. A comparison of nonionic versus ionic contrast media: results of a retrospective, multicenter study. Midwest Pancreaticobiliary Study Group. *Gastrointest Endosc* 1995;42:312–16.
31. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. *N Engl J Med* 1996;335:909–18.
32. Escourrou J, Cordova JA, Lazorthes F, Frexinos J, Ribet A. Early and late complications after endoscopic sphincterotomy for biliary lithiasis with and without the gallbladder "in situ." *Gut* 1984;25:598–602.
33. Masci E, Mariani A, Curioni S, Testoni PA. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. *Endoscopy* 2003;35(10):830–4.
34. Sherman S, Ruffolo TA, Hawes RH, Lehman GA. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. *Gastroenterology* 1991;101(4):1068–75.
35. Chen YK, Foliente RL, Santoro MJ, Walter MH, Collen MJ. Endoscopic sphincterotomy-induced pancreatitis: increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction. *Am J Gastroenterol* 1994;89(3):327–33.
36. Dickinson RJ, Davies S. Post-ERCP pancreatitis and hyperamylasaemia: the role of operative and patient factors. *Eur J Gastroenterol Hepatol* 1998;10(5):423–8.
37. Deans GT, Sedman P, Martin DF, Royston CM, Leow CK, Thomas WE, Brough WA. Are complications of endoscopic sphincterotomy age related? *Gut* 1997;41(4):545–8.
38. De Palma GD, Catanzano C. Use of corticosteroids in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. *Am J Gastroenterol* 1999;94(4):982–5.
39. Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL, Fan ST. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. *Gastrointest Endosc* 1999;49(5):593–8.
40. Roszler MH, Campbell WL. Post-ERCP pancreatitis: association with urographic visualization during ERCP. *Radiology* 1985;157:595–8.
41. Johnson GK, Geenen JE, Johanson JF, Sherman S, Hogan WJ, Cass O. Evaluation of post-ERCP pancreatitis: potential causes noted during controlled study of differing contrast media. Midwest Pancreaticobiliary Study Group. *Gastrointest Endosc* 1997;46:217–22.
42. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy — Italian Group. *N Engl J Med* 1996;335(13):919–23.
43. Maldonado ME, Brady PG, Mamel JJ, Robinson B. Incidence of pancreatitis in patients undergoing sphincter of Oddi manometry (SOM). *Am J Gastroenterol* 1999;94:387–90.
44. Goebel C, Hardt P, Doppl W, Temme H, Hackstein N, Klor HU. Frequency of pancreatitis after endoscopic retrograde cholangiopancreatography with iopromid or iotrolan: a randomized trial. *Eur Radiol* 2000;10:677–80.
45. Nakajima M, Kizu M, Akasaka Y, Kawai K. Five years' experience of endoscopic sphincterotomy in Japan: a collective study from 25 centres. *Endoscopy* 1979;11:138–41.
46. Atomi H, Saisyo H, Hayakawa T, Akashi T, Kumata S, Shiratori K, et al. Complications of endoscopic retrograde cholangiopancreatography; 2000 Report. Tokyo: The Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour and Welfare; 2001. p. 47–53.
47. Japan Gastroenterological Endoscopy Society. ERCP-related guidelines for preventing complications of endoscopic retrograde cholangiopancreatography. *Gastroenterol Endosc* 2000;42:2294–301.
48. White MT, Morgan A, Hopton D. Postoperative pancreatitis: a study of 70 cases. *Am J Surg* 1970;120:132–7.
49. Thompson JS, Bragg LE, Hodgson PE, Rikkers LF. Postoperative pancreatitis. *Surg Gynecol Obstet* 1988;167:377–80.
50. Imrie CW, Dickson AP. Postoperative pancreatitis. In: Howard JM, Jordan GL, Reber HA, editors. *Surgical disease of the pancreas*. Philadelphia: Lea and Febiger; 1987. p. 332–41.
51. Z'graggen K, Aronsky D, Maurer CA, Klaiber C, Baer HU. Acute postoperative pancreatitis after laparoscopic cholecystectomy. Results of the Prospective Swiss Association of Laparoscopic and Thoracoscopic Surgery Study. *Arch Surg* 1997;132:1026–30.
52. Fernandez-del Castillo C, Harringer W, Warshaw AL, Vlahakes GJ, Koski G, Zaslavsky AM, Rattner DW. Risk factors for pancreatic cellular injury after cardiopulmonary bypass. *N Engl J Med* 1991;325:382–7.
53. Lefor AT, Vuocolo P, Parker FJ, Sillin LF. Pancreatic complications following cardiopulmonary bypass. Factors influencing mortality. *Arch Surg* 1992;127:1225–30.
54. Babineau TJ, Hernandez E, Forse RA, Bistran BR. Symptomatic hyperlipasemia after cardiopulmonary bypass: implications for enteral nutritional support. *Nutrition* 1993;9:237–9.
55. Egleston CV, Wood AE, Gorey TF, McGovern EM. Gastrointestinal complications after cardiac surgery. *Ann R Coll Surg Engl* 1993;75:52–6.
56. Hashimoto L, Walsh RM. Acute pancreatitis after aortic surgery. *Am Surg* 1999;65:423–6.
57. Simic O, Strathausen S, Hess W, Ostermeyer J. Incidence and prognosis of abdominal complications after cardiopulmonary bypass. *Cardiovasc Surg* 1999;7:419–24.
58. Koep LJ, Starzl TE, Weil R III. Gastrointestinal complications of hepatic transplantation. *Transpl Proc* 1979;11:257–61.
59. Meyers WC, Harris N, Stein S, Brooks M, Jones RS, Thompson WM, et al. Alimentary tract complications after renal transplantation. *Ann Surg* 1979;190:535–42.
60. Benoit G, Moukarzel M, Verdelli G, Hiesse C, Buffet C, Bensadoun H, et al. Gastrointestinal complications in renal transplantation. *Transpl Int* 1993;6:45–9.
61. Ramsey PS, Podratz KC. Acute pancreatitis after gynecologic and obstetric surgery. *Am J Obstet Gynecol* 1999;181:542–6.
62. Sackmann M, Pauletzki J, Sauerbruch T, Holl J, Schelling G, Paumgartner G. The Munich Gallbladder Lithotripsy Study. Results of the first 5 years with 711 patients. *Ann Intern Med* 1991;114:290–6.
63. Kolmannskog F, Kolbenstedt AN, Schrupf E, Hanssen LE. Side effects and complications after hepatic artery embolization in the carcinoid syndrome. *Scand J Gastroenterol* 1991;26:557–62.

64. Savader SJ, Venbrux AC, Robbins KV, Gittelsohn AM, Osterman FA. Pancreatic response to percutaneous biliary drainage: retrospective study. *Radiology* 1991;178:343–6.
65. Kadakia SC, Starnes E. Comparison of 10 French gauge stent with 11.5 French gauge stent in patients with biliary tract diseases. *Gastrointest Endosc* 1992;38:454–9.
66. Noyes RD, Weiss SM, Krall JM, Sause WT, Owens JR, Wolkov HB, et al. Surgical complications of intraoperative radiation therapy: the Radiation Therapy Oncology Group experience. *J Surg Oncol* 1992;50:209–15.
67. Pannekeet MM, Krediet RT, Boeschoten EW, Arisz L. Acute pancreatitis during CAPD in the Netherlands. *Nephrol Dial Transplant* 1993;8:1376–81.
68. Gupta A, Yuan ZY, Balaskas EV, Khanna R, Oreopoulos DG. CAPD and pancreatitis: no connection. *Perit Dial Int* 1992;12:309–16.
69. Mallory A, Kern FJ. Drug-induced pancreatitis: a critical review. *Gastroenterology* 1980;78:813–20.
70. Banerjee AK, Patel KJ, Grainger SL. Drug-induced acute pancreatitis: a critical review. *Med Toxicol Adverse Drug Exp* 1989;4:186–98.
71. Maxson CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2',3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome. *Am J Gastroenterol* 1992;87:708–13.
72. Colin JD, Langman MJ, Lawson DH, Logan RF, Paterson KR, Vessey MP. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. *Gut* 1992;33:1280–4.
73. Butler KM, Venzon D, Henry N, Husson RN, Mueller BU, Balis FM, et al. Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine. *Pediatrics* 1993;91:747–51.
74. Frick TW, Speiser DE, Bimmler D, Largiader F. Drug-induced acute pancreatitis: further criticism. *Dig Dis* 1993;11:113–32.
75. Underwood TW, Frye CB. Drug-induced pancreatitis. *Clin Pharmacol* 1993;12:440–8.
76. Fukui Y, Shiozaki Y. Drug-induced pancreatitis in Japan (in Japanese). *Nippon Shokakibyō Gakkai Zasshi* (The Japanese journal of gastro-enterology, in Japanese) 1994;91:2157–65.
77. McArthur KE. Review article: drug-induced pancreatitis. *Aliment Pharmacol Ther* 1996;10:23–38.
78. Runzi M, Layer P. Drug-associated pancreatitis: facts and fiction. *Pancreas* 1996;13:100–9.
79. Wilmsink T, Frick TW. Drug-induced pancreatitis. *Drug Safety* 1996;14:406–23.
80. Steinberg W, Tenner S. Acute pancreatitis. *N Engl J Med* 1994;330:1198–210.
81. Haber CJ, Meltzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. *Gastroenterology* 1986;91(4):982–6.
82. Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. *Am J Gastroenterol* 2003;98(6):1305–8.
83. Miller TL, Winter HS, Luginbuhl LM, Orav EJ, McIntosh K. Pancreatitis in pediatric human immunodeficiency virus infection. *J Pediatr* 1992;120(2 Pt 1):223–7.
84. Dutta SK, Ting CD, Lai LL. Study of prevalence, severity, and etiological factors associated with acute pancreatitis in patients infected with human immunodeficiency virus. *Am J Gastroenterol* 1997;92(11):2044–8.
85. Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. *Am J Med* 1999;107(1):78–84.
86. Blomgren KB, Sundstrom A, Steineck G, Genell S, Sjostedt S, Wiholm BE. A Swedish case-control network for studies of drug-induced morbidity — acute pancreatitis. *Eur J Clin Pharmacol* 2002;58(4):275–83.
87. Bush ZM, Kosmiski LA. Acute pancreatitis in HIV-infected patients: are etiologies changing since the introduction of protease inhibitor therapy? *Pancreas* 2003;27(1):e1–5.
88. Dickson AP, O'Neill J, Imrie CW. Hyperlipidaemia, alcohol abuse, and acute pancreatitis. *Br J Surg* 1984;1:685–8.
89. Murase T. Pathophysiology and gene analysis of serum lipoprotein disorders: lipoprotein lipase deficiency (in Japanese). *Nippon Rinsho* (Japanese journal of clinical medicine, in Japanese) 1994;52:3221–7.
90. Santamarina FS, Brewer HJ. The familial hyperchylomicronemia syndrome. New insights into underlying genetic defects. *JAMA* 1991;265:904–8.
91. Mirete G, Masia M, Gutierrez F, Mora A, Escolano C, Maestre A. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. *Eur J Clin Microbiol Infect Dis* 1998;17(11):810–11.
92. Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis. *Clin Infect Dis* 1999;28(1):161–2.
93. Di Martino V, Ezenfis J, Benhamou Y, Bernard B, Opolon P, Bricaire F, Poynard T. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. *AIDS* 1999;13(11):1421–3.
94. Lowenfels AB, Maisonneuve P, DiMaggio EP, Elitsur Y, Gates LK Jr, Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. *J Natl Cancer Inst* 1997;89:442–6.
95. Toskes PP. Hyperlipidemic pancreatitis. *Gastroenterol Clin North Am* 1990;19(4):783–91.
96. Gorry MC, Gabbazadeh D, Furey W, Gates LK Jr, Preston RA, Aston CE, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. *Gastroenterology* 1997;113:1063–8.
97. Manocha AP, Sossenheimer M, Martin SP, Sherman KE, Venkatesan T, Whitcomb DC, Ulrich CD II. Prevalence and predictors of severe acute pancreatitis in patients with acquired immune deficiency syndrome (AIDS). *Am J Gastroenterol* 1999;94(3):784–9.
98. Ros E, Navarro S, Bru C, Garcia PA, Valderrama R. Occult microlithiasis in “idiopathic” acute pancreatitis: prevention of relapses by cholecystectomy or ursodeoxycholic acid therapy. *Gastroenterology* 1991;101:1701–9.
99. Lee SP, Nicholls JF, Park HZ. Biliary sludge as a cause of acute pancreatitis. *N Engl J Med* 1992;326(9):589–93.
100. Ramin KD, Ramin SM, Richey SD, Cunningham FG. Acute pancreatitis in pregnancy. *Am J Obstet Gynecol* 1995;173:187–91.
101. Scott LD. Gallstone disease and pancreatitis in pregnancy. *Gastroenterol Clin North Am* 1992;21:803–15.
102. Klein K. Pancreatitis in pregnancy. In: Rustgi V, Cooper J, editors. *Gastrointestinal and hepatic complications in pregnancy*. New York: Wiley; 1986.
103. Walters RL, Gaspard DJ, Germann TD. Traumatic pancreatitis. *Am J Surg* 1966;111:364–8.
104. Berly MH, Wilmot CB. Acute abdominal emergencies during the first four weeks after spinal cord injury. *Arch Phys Med Rehabil* 1984;65:687–90.
105. Parenti DM, Steinberg W, Kang P. Infectious causes of acute pancreatitis. *Pancreas* 1996;13:356–71.
106. Pascual-Ramos V, Duarte-Rojo A, Villa AR, Hernandez-Cruz B, Alarcon-Segovia D, Alcocer-Varela J, Robles-Diaz G. Systemic lupus erythematosus as a cause and prognostic factor of acute pancreatitis. *J Rheumatol* 2004;31(4):707–12.
107. Saab S, Corr MP, Weisman MH. Corticosteroids and systemic lupus erythematosus pancreatitis: a case series. *J Rheumatol* 1998;25:801–6.
108. Serrano LM, Yebra BM, Lopez BE, Sanchez VI, Albarran HF, Manzano EL, et al. Acute pancreatitis and systemic lupus erythematosus: necropsy of a case and review of the pancreatic vascular lesions. *Am J Gastroenterol* 1991;86:764–7.

109. Ben AH, Pollack S, Nagachandran P, Lashevsky I, Yarnitsky D, Edoute Y. Reversible pancreatitis, hepatitis, and peripheral polyneuropathy associated with parenteral gold therapy. *J Rheumatol* 1999;26:2049–50.
110. Tsianos EV, Moutsopoulos HM. Sjogren's syndrome and the gut. *Baillieres Clin Rheumatol* 1989;3:357–70.
111. Sartori N, Lohr M, Basan B, Holle A, Liebe S. Pancreatitis in systemic scleroderma. *Z Gastroenterol* 1997;35:677–80.
112. Matsumoto J, Haritani M, Nishimaki E, Sendoh K, Minamiya Y, Nakanishi, et al. Acute pancreatitis accompanied by Sjogren's syndrome and systemic sclerosis (in Japanese). *Ryumachi (Rheumatism)* 2000;40:620–6.
113. Shearer MG, Imrie CW. Parathyroid hormone levels, hyperparathyroidism, and acute pancreatitis. *Br J Surg* 1986;73:282–4.
114. Carnaille B, Oudar C, Pattou F, Combemale F, Rocha J, Proye C. Pancreatitis and primary hyperparathyroidism: forty cases. *Aust N Z J Surg* 1998;68:117–19.
115. van Lanschot JJ, Bruining HA. Primary hyperparathyroidism and pancreatitis. *Neth J Surg* 1984;36:38–41.
116. Shepherd JJ. Hyperparathyroidism presenting as pancreatitis or complicated by postoperative pancreatitis. *Aust N Z J Surg* 1996;66:85–7.
117. Rutsky EA, Robards M, Van DJ, Rostand SG. Acute pancreatitis in patients with end-stage renal disease without transplantation. *Arch Intern Med* 1986;146:1741–5.
118. Pitchumoni CS, Arguello P, Agarwal N, Yoo J. Acute pancreatitis in chronic renal failure. *Am J Gastroenterol* 1996;91:2477–82.
119. Kelly TR. Gallstone pancreatitis. Local predisposing factors. *Ann Surg* 1984;200(4):479–85.
120. Police AM, Waxman K, Smolin M, Tominaga G, Landau S, Mason R. Development of gallstone pancreatitis. The role of the common channel. *Arch Surg* 1984;119:1299–300.
121. Armstrong CP, Taylor TV, Jeacock J, Lucas S. The biliary tract in patients with acute gallstone pancreatitis. *Br J Surg* 1985;72:551–5.
122. Nowak A, Nowakowska DE, Rybicka J. Patency of the Santorini duct and acute biliary pancreatitis: retrospective ERCP study. *Endoscopy* 1990;22:124–6.
123. Cotton PB. Congenital anomaly of pancreas divisum as cause of obstructive pain and pancreatitis. *Gut* 1980;21:105–14.
124. Britt LG, Samuels AD, Johnson JJ. Pancreas divisum: is it a surgical disease? *Ann Surg* 1983;197:654–62.
125. Uomo G, Rabitti PG, Laccetti M, Visconti M. Pancreaticocholedochal junction and pancreatic duct system morphology in acute biliary pancreatitis: retrospective study with early ERCP. *Int J Pancreatol* 1993;13:187–91.
126. Lans JI, Geenen JE, Johanson JF, Hogan WJ. Endoscopic therapy in patients with pancreas divisum and acute pancreatitis: a prospective, randomized, controlled clinical trial. *Gastrointest Endosc* 1992;38(4):430–4.
127. Stephens FO, Pauline GJ. Choledochocoele: an unusual type of choledochal cyst which presented as acute pancreatitis. *Aust N Z J Surg* 1966;36:124–7.
128. Frexes M, Neblett W III, Holcomb GJ. Spectrum of biliary disease in childhood. *South Med J* 1986;79:1342–9.
129. Bradley ER, Stephan RN. Accessory duct sphincteroplasty is preferred for long-term prevention of recurrent acute pancreatitis in patients with pancreas divisum. *J Am Coll Surg* 1996;183:65–70.
130. Neblett WR, O'Neill JJ. Surgical management of recurrent pancreatitis in children with pancreas divisum. *Ann Surg* 2000;231:899–908.
131. van der Spuy S. The relationship between juxtapapillary diverticula and biliary calculi. An endoscopic study. *Endoscopy* 1979;11:197–202.
132. Rubesin SE, Furth EE, Birnbaum BA. Ectopic pancreas complicated by pancreatitis and pseudocyst formation mimicking jejunal diverticulitis. *Br J Radiol* 1997;70:311–13.
133. Lad RJ, Fitzgerald P, Jacobson K. An unusual cause of recurrent pancreatitis: duodenal duplication cyst. *Can J Gastroenterol* 2000;14:341–5.
134. Landen S, Bardaxoglou E, Maddern GJ, Delugeau V, Gosselin M, Launois B. Caroli's disease: a surgical dilemma. *Acta Chir Belg* 1993;93:224–6.
135. Boyle JM, McLeod ME. Pancreatic cancer presenting as pancreatitis of pregnancy. Case report. *Am J Gastroenterol* 1978;70(4):371–3.
136. Matsushita S, Sawabu N, Yoneda M, Makino H, Yokawa S, Nakagen M, et al. Two cases of pancreatic cancer with acute pancreatitis (in Japanese). *Nippon Shokakibyo Gakkai Zasshi (The Japanese journal of gastro-enterology, in Japanese)* 1979;76(7):1545–9.
137. Grimley RP. Acute pancreatitis and pancreatic cancer. *Clin Oncol* 1978;4:373–7.
138. Pelli H, Sand J, Laippala P. Long-term follow-up after the first episode of acute alcoholic pancreatitis: time course and risk factors for recurrence. *Scand J Gastroenterol* 2000;35:552–5.
139. Ranson JH. The timing of biliary surgery in acute pancreatitis. *Ann Surg* 1979;189:654–63.
140. Frei GJ, Frei VT, Thirly RC, McClelland RN. Biliary pancreatitis: clinical presentation and surgical management. *Am J Surg* 1986;151:170–5.
141. DeIorio AJ, Vitale GC, Reynolds M, Larson GM. Acute biliary pancreatitis. The roles of laparoscopic cholecystectomy and endoscopic retrograde cholangiopancreatography. *Surg Endosc* 1995;9:392–6.
142. Ballinger AB, Barnes E, Alstead EM, Fairclough PD. Is intervention necessary after a first episode of acute idiopathic pancreatitis? *Gut* 1996;38:293–5.
143. Kuroda K, Izumi R, Hayakawa T, et al. Long-term outcomes of acute pancreatitis: 1993 Report. Tokyo: The Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour and Welfare; 1993. p. 30–3.
144. Madsen OG, Schmidt A. Acute pancreatitis. A study of 122 patients with acute pancreatitis observed for 5–15 years. *World J Surg* 1979;3:345–52.
145. Malecka PE, Juszynski A, Wilamski E. The natural course of acute gallstone pancreatitis. *Mater Med Pol* 1996;28:8–12.
146. Angelini G, Cavallini G, Pederzoli P, Bovo P, Bassi C, Di Francesco V, et al. Long-term outcome of acute pancreatitis: retrospective study with 118 patients. *Digestion* 1993;54:143–7.
147. Corfield AP, Cooper MJ, Williamson RC. Acute pancreatitis: a lethal disease of increasing incidence. *Gut* 1985;26:724–9.
148. Wilson C, Imrie CW. Deaths from acute pancreatitis: why do we miss the diagnosis so frequently? *Int J Pancreatol* 1988;3:273–81.
149. Mann DV, Hershman MJ, Hittinger R, Glazer G. Multicentre audit of death from acute pancreatitis. *Br J Surg* 1994;81:890–3.
150. Fan ST, Choi TK, Lai CS, Wong J. Influence of age on the mortality from acute pancreatitis. *Br J Surg* 1988;75:463–6.
151. McKay CJ, Evans S, Sinclair M, Carter CR, Imrie CW. High early mortality rate from acute pancreatitis in Scotland, 1984–1995. *Br J Surg* 1999;86:1302–5.
152. Talamini G, Bassi C, Falconi M, Sartori N, Frulloni L, Di Francesco V, et al. Risk of death from acute pancreatitis. Role of early, simple "routine" data. *Int J Pancreatol* 1996;19(1):15–24.
153. Lowham A, Lavelle J, Leese T. Mortality from acute pancreatitis. Late septic deaths can be avoided but some early deaths still occur. *Int J Pancreatol* 1999;25(2):103–6.
154. Mutinga M, Rosenbluth A, Tenner SM, Odze RR, Sica GT, Banks PA. Does mortality occur early or late in acute pancreatitis? *Int J Pancreatol* 2000;28(2):91–5.
155. Blum T, Maisonneuve P, Lowenfels AB, Lankisch PG. Fatal outcome in acute pancreatitis: its occurrence and early prediction. *Pancreatol* 2001;1(3):237–41.
156. Kandasami P, Harunarashid H, Kaur H. Acute pancreatitis in a multi-ethnic population. *Singapore Med J* 2002;43(6):284–8.

157. Otsuki M, Ito T, Koizumi M, Shimosegawa T. Mortality and deterioration factors of acute pancreatitis: A multicenter analysis of death from acute pancreatitis (in Japanese). *Suizo* 2005;210(1):17–30.
158. Matsuno M, editor. Guidelines for management of severe acute pancreatitis: pathophysiology of severe acute pancreatitis. The Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour and Welfare. Tokyo: Igaku Tosho; 1997. p. 13–17.
159. Gullo L, Migliori M, Pezzilli R, Olah A, Farkas G, Levy P, et al. An update on recurrent acute pancreatitis: data from five European countries. *Am J Gastroenterol* 2002;97(8):1959–62.
160. Balthazar EJ, Freeny PC, vanSonnenberg E. Imaging and intervention in acute pancreatitis. *Radiology* 1994;193(2):297–306.
161. Uhl W, Roggo A, Kirschstein T, Anghelacopoulos SE, Gloor B, Muller CA, Malfertheiner P, Buchler MW. Influence of contrast-enhanced computed tomography on course and outcome in patients with acute pancreatitis. *Pancreas* 2002;24(2):191–7.
162. Sunamura M, Lozonschi L, Takeda K, Kobari M, Matsuno S. Criteria for diagnosis of acute pancreatitis in Japan and clinical implications. *Pancreas* 1998;16(3):243–9.
163. Renner IG, Savage WT III, Pantoja JL, Renner VJ. Death due to acute pancreatitis. A retrospective analysis of 405 autopsy cases. *Dig Dis Sci* 1985;30:1005–18.
164. Lankisch PG, Burchard-Reckert S, Petersen M, Lehnick D, Schirren CA, Kohler H, et al. Morbidity and mortality in 602 patients with acute pancreatitis seen between the years 1980–1994. *Z Gastroenterol* 1996;34:371–7.
165. Beger HG, Bittner R, Block S, Buchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. *Gastroenterology* 1986;91:433–8.
166. Gloor B, Muller CA, Worni M, Martignoni ME, Uhl W, Buchler MW. Late mortality in patients with severe acute pancreatitis. *Br J Surg* 2001;88(7):975–9.
167. McKay CJ, Imrie CW. The continuing challenge of early mortality in acute pancreatitis. *Br J Surg* 2004;91(10):1243–4.
168. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, et al. Double-blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. *Gut* 2001;48(1):62–9.
169. Ogawa M, Hirota M, Hayakawa T, Matsuno S, Watanabe S, Atomi Y, et al. Development and use of a new staging system for severe acute pancreatitis based on a nationwide survey in Japan. *Pancreas* 2002;25(4):325–30.
170. Perez A, Whang EE, Brooks DC, Moore FD Jr, Hughes MD, Sica GT, et al. Is severity of necrotizing pancreatitis increased in extended necrosis and infected necrosis? *Pancreas* 2002;25(3):229–33.
171. Banks PA, Gerzof SG, Langevin RE, Silverman SG, Sica GT, Hughes MD. CT-guided aspiration of suspected pancreatic infection: bacteriology and clinical outcome. *Int J Pancreatol* 1995;18(3):265–70.
172. Allardyce DB. Incidence of necrotizing pancreatitis and factors related to mortality. *Am J Surg* 1987;154(3):295–9.
173. Karimani I, Porter KA, Langevin RE, Banks PA. Prognostic factors in sterile pancreatic necrosis. *Gastroenterology* 1992;103(5):1636–40.
174. Bradley EL III, Allen K. Retrospective longitudinal study of observation versus surgical intervention in the management of necrotizing pancreatitis. *Am J Surg* 1991;161(1):19–24.
175. Rattner DW, Legermate DA, Lee MJ, Mueller PR, Warshaw AL. Early surgical debridement of symptomatic pancreatic necrosis is beneficial irrespective of infection. *Am J Surg* 1992;163(1):105–9.
176. Lankisch PG, Warnecke B, Bruns D, Werner HM, Grossmann F, Struckmann K, et al. The APACHE II score is unreliable to diagnose necrotizing pancreatitis on admission to hospital. *Pancreas* 2002;24(3):217–22.
177. Ogawa M, Hirota M, Atomi H, Otsuki M, Shimazaki S, Sugiyama M, et al. Survey of acute pancreatitis: 2000 Report. Tokyo: The Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour and Welfare; 2001. p. 17–33.
178. Lumsden A, Bradley EL III. Secondary pancreatic infections. *Surg Gynecol Obstet* 1990;170:459–67.
179. Angelini G, Pederzoli P, Caliani S, Fratton S, Brocco G, Marzoli G, et al. Long-term outcome of acute necrohemorrhagic pancreatitis. A 4-year follow-up. *Digestion* 1984;30:131–7.
180. Doepel M, Eriksson J, Halme L, Kumpulainen T, Hockerstedt K. Good long-term results in patients surviving severe acute pancreatitis. *Br J Surg* 1993;80:1583–6.
181. Tsiotos G, Luque-de Leon E, Sarr M. Long-term outcome of necrotizing pancreatitis treated by necrosectomy. *Br J Surg* 1998;85:1650–3.
182. Eriksson J, Doepel M, Widen E, Halme L, Ekstrand A, Groop L, et al. Pancreatic surgery, not pancreatitis, is the primary cause of diabetes after acute fulminant pancreatitis. *Gut* 1992;33:843–7.
183. Kashima T, Kuroda Y, Ogawa M. Survey of long-term outcomes in acute pancreatitis: 2001 Report. Tokyo: The Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour and Welfare; 2002. p. 54–9.